| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2409797 | Vaccine | 2007 | 4 Pages |
Abstract
A phase II open and parallel reactogenicity, immunogenicity and safety trivalent meningitis vaccine (Mencevax) trial was conducted on 413 volunteer 2–29-year-old rural residents in Ethiopia in November/December 2005. Adverse events (AE) were monitored at 1 h, 1, 2, 3, 7 and 28 days after vaccination. No serious AE occurred except for burn injury (one) and severe malaria (one) after day 28. Irritability (45/411), loss of appetite (27/411), pain at injection site (26/412), dizziness (18/409), crying (14/411), insomnia, headache and diarrhoea (13/411) were the most frequent AEs. Overall, the vaccine is safe in the age groups studied.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Abraham Aseffa, Ahmed Bedru, Lawrence Yamuah, Demis Arga, Alemayehu Worku, Daniel Chandramohan, Christopher B. Nelson, Howard D. Engers,